Jose Maria Ribera

Summary

Country: Spain

Publications

  1. doi request reprint Treatment of young patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia using increased dose of imatinib and deintensified chemotherapy before allogeneic stem cell transplantation
    Josep Maria Ribera
    Department of Haematology, ICO Hospital Germans Trias i Pujol, Jose Carreras Leukaemia Research Institute, Universitat Autonoma de Barcelona, Barcelona, Spain
    Br J Haematol 159:78-81. 2012
  2. ncbi request reprint Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA
    Josep Maria Ribera
    Josep Maria Ribera, Albert Oriol, Mireia Morgades, and Evarist Feliu, Institut Català d Oncologia Hospital Germans Trias i Pujol Jose Carreras Research Institute Salut Brunet, Hospital de Sant Pau Jordi Esteve, Hospital Clínic Pere Barba, Hospital Vall d Hebron, Barcelona Pau Montesinos, Hospital Universitario La Fe Mar Tormo, Hospital Clinico, Valencia Josep Sarrà, Institut Català d Oncologia Hospital Duran i Reynals, L Hospitalet de Llobregat José González Campos, Hospital Universitario Virgen del Rocio, Sevilla Pascual Fernández Abellán, Hospital General, Alicante Ramon Guàrdia, Institut Català d Oncologia Hospital Josep Trueta, Girona María Teresa Bernal, Hospital Central de Asturias, Oviedo María José Moreno, Hospital Virgen de la Victoria, Málaga Arancha Bermúdez, Hospital Marques de Valdecilla, Santander Antonia Cladera, Hospital Son Llatzer, Palma de Mallorca Lourdes Escoda, Hospital Joan XXIII, Tarragona Raimundo García Boyero, Hospital General, Castellón Eloy del Potro, Hospital Clínico San Carlos Carlos Grande, General Hospital
    J Clin Oncol 32:1595-604. 2014
  3. pmc Acute lymphoblastic leukemia in adults
    Josep Maria Ribera
    Clinical Hematology Department, Institut Catala d Oncologia, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Pediatr Rep 3:e1. 2011
  4. doi request reprint Dose-intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study (Burkimab)
    Josep Maria Ribera
    Hematology Department, Institut Català d Oncologia Hospital Germans Trias i Pujol, José Carreras Leukemia Research Institute, Badalona, Spain
    Cancer 119:1660-8. 2013
  5. doi request reprint Optimal approach to treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: how to best use all the available tools
    Josep Maria Ribera
    Clinical Hematology Department, ICO Hospital Germans Trias i Pujol, José Carreras Leukemia Research Institute, Badalona, Spain
    Leuk Lymphoma 54:21-7. 2013
  6. ncbi request reprint A step forward in therapy for ALL in infants
    Josep Maria Ribera
    Clinical Haematology Department, Institut Català d Oncologia Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Lancet 370:198-200. 2007
  7. ncbi request reprint Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial
    Josep Maria Ribera
    Haematology Department, Institut Català d Oncologia Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Br J Haematol 140:411-9. 2008
  8. doi request reprint Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96
    Josep Maria Ribera
    Servicio de Hematología Clínica, Institut Català d Oncologia Hospital Universitari Germans Trias i Pujol, C Canyet s n, 08916 Badalona, Spain
    J Clin Oncol 26:1843-9. 2008
  9. pmc Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial
    Josep Maria Ribera
    Department of Hematology of the Hospitals Institut Català d Oncologia Hospital Germans Trias i Pujol, Badalona, Spain
    Haematologica 95:87-95. 2010
  10. ncbi request reprint Acute lymphoblastic leukemia in adolescents and young adults
    Josep Maria Ribera
    Clinical Hematology Department, Institut Catala d Oncologia, Hospital Universitari Germans Trias i Pujol, Badalona, Universitat Autonoma de Barcelona, C Canyet s n, 08916 Badalona, Spain
    Hematol Oncol Clin North Am 23:1033-42, vi. 2009

Collaborators

Detail Information

Publications32

  1. doi request reprint Treatment of young patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia using increased dose of imatinib and deintensified chemotherapy before allogeneic stem cell transplantation
    Josep Maria Ribera
    Department of Haematology, ICO Hospital Germans Trias i Pujol, Jose Carreras Leukaemia Research Institute, Universitat Autonoma de Barcelona, Barcelona, Spain
    Br J Haematol 159:78-81. 2012
    ..78%). The reduction in early death, relapse before SCT and transplant-related mortality observed in the ALL-Ph-08 trial resulted in an improved 2-year event-free survival (63% vs. 37%, P = 0·009)...
  2. ncbi request reprint Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA
    Josep Maria Ribera
    Josep Maria Ribera, Albert Oriol, Mireia Morgades, and Evarist Feliu, Institut Català d Oncologia Hospital Germans Trias i Pujol Jose Carreras Research Institute Salut Brunet, Hospital de Sant Pau Jordi Esteve, Hospital Clínic Pere Barba, Hospital Vall d Hebron, Barcelona Pau Montesinos, Hospital Universitario La Fe Mar Tormo, Hospital Clinico, Valencia Josep Sarrà, Institut Català d Oncologia Hospital Duran i Reynals, L Hospitalet de Llobregat José González Campos, Hospital Universitario Virgen del Rocio, Sevilla Pascual Fernández Abellán, Hospital General, Alicante Ramon Guàrdia, Institut Català d Oncologia Hospital Josep Trueta, Girona María Teresa Bernal, Hospital Central de Asturias, Oviedo María José Moreno, Hospital Virgen de la Victoria, Málaga Arancha Bermúdez, Hospital Marques de Valdecilla, Santander Antonia Cladera, Hospital Son Llatzer, Palma de Mallorca Lourdes Escoda, Hospital Joan XXIII, Tarragona Raimundo García Boyero, Hospital General, Castellón Eloy del Potro, Hospital Clínico San Carlos Carlos Grande, General Hospital
    J Clin Oncol 32:1595-604. 2014
    ....
  3. pmc Acute lymphoblastic leukemia in adults
    Josep Maria Ribera
    Clinical Hematology Department, Institut Catala d Oncologia, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Pediatr Rep 3:e1. 2011
    ..Advances in the genetic and epigenetic mechanisms of the disease provide hope that targeted therapies can more effectively treat the disease with less toxicity...
  4. doi request reprint Dose-intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study (Burkimab)
    Josep Maria Ribera
    Hematology Department, Institut Català d Oncologia Hospital Germans Trias i Pujol, José Carreras Leukemia Research Institute, Badalona, Spain
    Cancer 119:1660-8. 2013
    ..This study prospectively evaluated and compared the outcome and toxicity of human immunodeficiency virus (HIV)-positive and HIV-negative patients with BL who were treated in an intensive immunochemotherapy-based and age-adapted trial...
  5. doi request reprint Optimal approach to treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: how to best use all the available tools
    Josep Maria Ribera
    Clinical Hematology Department, ICO Hospital Germans Trias i Pujol, José Carreras Leukemia Research Institute, Badalona, Spain
    Leuk Lymphoma 54:21-7. 2013
    ....
  6. ncbi request reprint A step forward in therapy for ALL in infants
    Josep Maria Ribera
    Clinical Haematology Department, Institut Català d Oncologia Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Lancet 370:198-200. 2007
  7. ncbi request reprint Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial
    Josep Maria Ribera
    Haematology Department, Institut Català d Oncologia Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Br J Haematol 140:411-9. 2008
    ..In HIV-related DLBCL R-CHOP is feasible, safe and effective. The prognosis depends on lymphoma-related parameters and on the response to HAART...
  8. doi request reprint Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96
    Josep Maria Ribera
    Servicio de Hematología Clínica, Institut Català d Oncologia Hospital Universitari Germans Trias i Pujol, C Canyet s n, 08916 Badalona, Spain
    J Clin Oncol 26:1843-9. 2008
    ..The ALL-96 protocol was addressed to compare the toxicity and results of a pediatric-based protocol in adolescents (age 15-18 years) and young adults (age 19-30 years) with standard-risk (SR) ALL...
  9. pmc Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial
    Josep Maria Ribera
    Department of Hematology of the Hospitals Institut Català d Oncologia Hospital Germans Trias i Pujol, Badalona, Spain
    Haematologica 95:87-95. 2010
    ....
  10. ncbi request reprint Acute lymphoblastic leukemia in adolescents and young adults
    Josep Maria Ribera
    Clinical Hematology Department, Institut Catala d Oncologia, Hospital Universitari Germans Trias i Pujol, Badalona, Universitat Autonoma de Barcelona, C Canyet s n, 08916 Badalona, Spain
    Hematol Oncol Clin North Am 23:1033-42, vi. 2009
    ..The type of treatment (pediatric-based versus adult-based) for AYA has recently been a matter of debate. In this article the biology and treatment of ALL in AYA is reviewed...
  11. ncbi request reprint Comparison of intensive chemotherapy, allogeneic, or autologous stem-cell transplantation as postremission treatment for children with very high risk acute lymphoblastic leukemia: PETHEMA ALL-93 Trial
    Jose Maria Ribera
    Servicio de Hematología Clínica, Institut Català d Oncologia Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    J Clin Oncol 25:16-24. 2007
    ..This randomized trial compared three options of postremission therapy: chemotherapy and allogeneic or autologous stem-cell transplantation (SCT)...
  12. doi request reprint Advances in acute lymphoblastic leukemia in adults
    Josep Maria Ribera
    Clinical Hematology Department, Institut Català d Oncologia Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Badalona and Universidad Autónoma de Barcelona, Barcelona, Spain
    Curr Opin Oncol 23:692-9. 2011
    ..This review will be focused on the advances in adult acute lymphoblastic leukemia (ALL) based on recently published articles...
  13. ncbi request reprint [The processes of manuscript evaluation and publication in Medicina Clínica. The editorial committee of Medicina Clínica]
    Josep M Ribera
    Med Clin (Barc) 125:3-7. 2005
    ..The present article provides a detailed description of the main technical and ethical issues involved in the processes of decision-making and publication of biomedical articles...
  14. ncbi request reprint High-dose infusional ifosfamide, etoposide plus methylprednisolone followed by dexamethasone, high-dose ara-C and cisplatinum and autologous stem cell transplantation for refractory or relapsed aggressive non-Hodgkin's lymphoma
    Antonio Salar
    Department of Clinical Hematology from Hospital del Mar, Hospital de la Santa Cruz y San Pablo, Hospital Germans Trias i Pujol, Hospital Clinic, Barcelona, Spain
    Haematologica 87:1028-35. 2002
    ..A salvage program including infusional high-dose ifosfamide plus etoposide (IFOVM) was evaluated in patients with refractory or relapsed aggressive non-Hodgkin's lymphoma...
  15. ncbi request reprint Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia
    Juan Manuel Sancho
    Clinical Hematology Department, Institut Català d Oncologia Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Eur J Haematol 78:102-10. 2007
    ..We present the results of treatment of Philadelphia chromosome-negative (Ph-) ALL patients over 55 yr treated in the PETHEMA ALL-96 trial...
  16. ncbi request reprint Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease
    Eva Gonzalez-Barca
    Clinical Hematology Department, Hospital Duran i Reynals, Institut Catala d Oncologia, Av Gran Via s n Km 2, 7, 08907 L Hospitalet de Llobregat, Barcelona, Spain
    Haematologica 92:1489-94. 2007
    ..The purpose of this trial was to evaluate the efficacy of treatment with extended doses of rituximab adapted to the response in patients with post-transplant lymphoproliferative disorders after solid organ transplantation...
  17. ncbi request reprint Lack of influence of human immunodeficiency virus infection status in the response to therapy and survival of adult patients with mature B-cell lymphoma or leukemia. Results of the PETHEMA-LAL3/97 study
    Albert Oriol
    Servei d Hematologia, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
    Haematologica 88:445-53. 2003
    ..A protocol was designed to treat all adult patients with mature B-cell lymphoma or leukemia with the aims of comparing the response to therapy and survival with regards to their HIV infection status...
  18. ncbi request reprint Advanced stage is the most important prognostic factor for survival in patients with systemic acquired immunodeficiency syndrome-related non-Hodgkin's Lymphoma treated with CHOP and highly active antiretroviral therapy
    José Tomás Navarro
    Department of Hematology, Institut Catala d Oncologia, Hospital Germans Trias i Pujol, Badalona
    Int J Hematol 86:337-42. 2007
    ..Patients with an advanced stage had a lower OS probability in a multivariate analysis (odds ratio, 4.24; 95% CI, 1.24- 14.57). Advanced stage was the main prognostic factor predicting survival in ARL treated with CHOP and HAART...
  19. ncbi request reprint [Neutropenic enterocolitis in adult patients with acute leukemia or stem cell transplant recipients: study of 7 cases]
    Montserrat Batlle
    Servicio de Hematología Clínica Institut Català d Oncologia Hospital Universitari Germans Trias i Pujol Badalona Barcelona España
    Med Clin (Barc) 129:660-3. 2007
    ..Neutropenic enterocolitis (NE) is a complication arising in neutropenic patients with acute leukemia or solid tumours while treated with intensive chemotherapy. The optimal therapeutic procedures have not been well established...
  20. ncbi request reprint [Similar prognosis for transplanted and non-transplanted patients with hematological malignancy admitted to the intensive care unit]
    Christelle Ferra
    Servicio de Hematología Clínica, Institut Català d Oncologia Hospital Germans Trias i Pujol, Badalona, Barcelona, Universidad Autonoma de Barcelona, Barcelona, Spain
    Med Clin (Barc) 130:573-5. 2008
    ..There is scarce information on the influence of stem cell transplantation (SCT) on the prognosis of patients with hematological malignancies admitted to an intensive care unit (ICU)...
  21. ncbi request reprint Hepatosplenic T-gammadelta lymphoma in a patient with Crohn's disease treated with azathioprine
    José Tomás Navarro
    Department of Haematology, Hospital Universitari Germans Trias i Pujol, Badalona, Universitat Autonoma de Barcelona, Barcelona, Spain
    Leuk Lymphoma 44:531-3. 2003
    ..The patient did not respond to intensive chemotherapy. This case shows the importance of ruling out HSgammadeltaTCL in patients with hepatosplenomegaly, B-symptoms and any immunosuppressive condition...
  22. ncbi request reprint In vivo quantification of response to treatment in patients with multiple myeloma by 1H magnetic resonance spectroscopy of bone marrow
    Albert Oriol
    Servei d Hematologia Clinica, Institut Catala d Oncologia, Hospital Universitari Germans Trias i Pujol, Ctra Canyet s n, 08916 Badalona, Barcelona, Spain
    MAGMA 20:93-101. 2007
    ..We performed proton MRS to patients with multiple myeloma (MM) at diagnosis and after treatment to investigate the possible correlation of MRS data with response to therapy...
  23. doi request reprint High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients
    Albert Oriol
    Department of Hematology, ICO Hospital Universitari Germans Trias i Pujol, Badalona Autonomous University, Barcelona, Spain
    Cancer 113:117-25. 2008
    ..The introduction of rituximab in BL therapeutic schemes has been scarcely explored. The outcome and toxicity of HIV-positive patients with BL treated in a rituximab and intensive chemotherapy-based trial was evaluated...
  24. ncbi request reprint Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial
    Josep Maria Ribera
    Hematology Department and Hematopoietic Progenitor Transplant Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Haematologica 87:154-66. 2002
    ..The objective of this study was to analyze the prognostic value of cytogenetic analysis in children and adults with high-risk acute lymphoblastic leukemia (HR-ALL) included in a prospective multicenter trial...
  25. ncbi request reprint Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranial irradiation for prophylaxis
    Juan Manuel Sancho
    Clinical Hematology Department Institut Catala d Oncologia Hospital Germans Trias i Pujol, Badalona, Universidad Autonoma de Barcelona, Barcelona, Spain
    Cancer 106:2540-6. 2006
    ..A lactate dehydrogenase value >1000 U/L was the only factor found to be associated with CNS recurrence. The prognosis for patients who develop CNS recurrence is poor, identical to that for patients who develop bone marrow recurrence...
  26. ncbi request reprint [Neurologic complications following hematopoietic stem cell transplantation. Study of 14 patients]
    Montserrat Batlle
    Servicio de Hematología Clínica, Institut Català d Oncologia Hospital Germans Trias i Pujol, Badalona, Spain
    Med Clin (Barc) 125:697-9. 2005
    ..We have analyzed the NC in 185 consecutive patients who underwent HSCT in a period of 5 years in a single HSCT Unit...
  27. ncbi request reprint Outcome and prognostic factors in patients with hematologic malignancies admitted to the intensive care unit: a single-center experience
    Christelle Ferra
    Clinical Hematology Department, Institut Catala d Oncologia, Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Spain
    Int J Hematol 85:195-202. 2007
    ..Age and underlying disease characteristics do not influence ICU outcome, which is mainly determined by hemodynamic and ventilatory status...
  28. ncbi request reprint Usefulness of tumor markers CA 125 and CA 15.3 at diagnosis and during follow-up in non-Hodgkin's lymphoma: study of 200 patients
    Montserrat Batlle
    Department of Hematology, Institut Catala d Oncologia, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Barcelona, Spain
    Leuk Lymphoma 46:1471-6. 2005
    ..0001), beta2-M (P = 0.013) and CA 125 (P = 0.025) whereas CA 15.3 was associated with a shorter EFS (P = 0.027). When elevated at diagnosis, CA 125 and CA 15.3 should be monitored during follow-up of patients with NHL...
  29. ncbi request reprint Oral solid form of primary effusion lymphoma mimicking plasmablastic lymphoma
    Jose Luis Mate
    Department of Pathology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain
    Hum Pathol 35:632-5. 2004
    ..This case illustrates the need for investigating HHV8 in any plasmablastic-looking lymphoma, especially in HIV-infected patients...
  30. ncbi request reprint Monosomy 7 with severe myelodysplasia developing during imatinib treatment of Philadelphia-positive chronic myeloid leukemia: two cases with a different outcome
    José Tomás Navarro
    Servei d Hematologia, Institut Catala d Oncologia, Hospital Germans Trias i Pujol, Badalona, Barcelona
    Am J Hematol 82:849-51. 2007
    ....
  31. ncbi request reprint Progressive multifocal leukoencephalopathy shortly after the diagnosis of follicular lymphoma in a patient treated with fludarabine
    Lluís Rodríguez
    Hematology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Universitat Autonoma de Barcelona, Spain
    Haematologica 87:ECR26. 2002
  32. ncbi request reprint Results of compassionate therapy with intrathecal depot liposomal cytarabine in acute myeloid leukemia meningeosis
    Juan Manuel Sancho
    Hematology Department, Institut Català d Oncologia Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Spain PETHEMA Group, Spanish Society of Hematology, Spain
    Int J Hematol 86:33-6. 2007
    ..Systemic therapy was given concomitantly in all cases, with high-dose cytarabine in 6. Clinical trials should establish the role of IT liposomal cytarabine in leukemic meningitis...